Short Interest in Aethlon Medical, Inc. (NASDAQ:AEMD) Drops By 46.7%

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 255,400 shares, a drop of 46.7% from the February 28th total of 479,400 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average trading volume of 3,140,000 shares, the short-interest ratio is currently 0.1 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Allegiance Financial Group Advisory Services LLC purchased a new position in shares of Aethlon Medical in the 4th quarter valued at about $26,000. Virtu Financial LLC acquired a new position in Aethlon Medical during the 4th quarter worth approximately $81,000. Renaissance Technologies LLC purchased a new stake in shares of Aethlon Medical in the 4th quarter valued at approximately $25,000. Sassicaia Capital Advisers LLC acquired a new stake in shares of Aethlon Medical in the 4th quarter valued at $31,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Aethlon Medical during the 4th quarter worth $186,000. 1.99% of the stock is owned by institutional investors and hedge funds.

Aethlon Medical Price Performance

Shares of NASDAQ:AEMD opened at $0.37 on Friday. The firm’s 50-day moving average is $0.56 and its two-hundred day moving average is $0.50. Aethlon Medical has a 1 year low of $0.24 and a 1 year high of $1.79. The firm has a market capitalization of $5.30 million, a PE ratio of -0.23 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last released its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. Analysts expect that Aethlon Medical will post -0.73 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on AEMD. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a report on Monday, March 10th. StockNews.com initiated coverage on Aethlon Medical in a research report on Friday. They set a “sell” rating for the company.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.